Home/Pipeline/Undisclosed TAA Targeted Sialidase

Undisclosed TAA Targeted Sialidase

Oncology

DiscoveryActive

Key Facts

Indication

Oncology

Phase

Discovery

Status

Active

Company

Palleon Pharmaceuticals

About Palleon Pharmaceuticals

Palleon Pharmaceuticals is at the forefront of glycobiology-based drug discovery, developing first-in-class therapies that degrade cell surface sialoglycans to treat cancer and autoimmune diseases. Its core technology, the EAGLE platform, fuses human sialidase enzymes with targeting antibodies to selectively remove immunosuppressive sugar molecules from diseased cells, rendering them vulnerable to immune attack. The company has advanced programs in both oncology (E-688) and immunology (E-602), supported by a strategic collaboration with Henlius. Palleon represents a private, preclinical-stage biotech targeting a significant new frontier in immuno-oncology and inflammation.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active